Enrico Costa

Outrageous prices of orphan drugs: a call for collaboration

Lucio Luzzatto, Hanna I. Hyry, Arrigo Schieppati et al. · The Lancet · 2018 · 160 citations

Pharmacy, Pharmaceutical Policy, Drug Law +10

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis

Enrico Costa, Silvia Girotti, Francesca Pauro et al. · Orphanet Journal of Rare Diseases · 2022 · 51 citations · Full text

Medicine, Pharmacology, Regulatory Policy +16

Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost

Enrico Costa, Prosper Tibalinda, Enrico Sterzi et al. · American Journal of Hematology · 2020 · 31 citations · Full text

Medicine, Health Policy, Hematology +17

Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury

Lucia De Franceschi, Enrico Costa, Francesco Dima et al. · European Journal of Internal Medicine · 2020 · 22 citations · Full text

Veterinary Medicine, Infectious Diseases, Infectious Disease Epidemiology +12

The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products

Gloria M. Palomo, Tomás Pose‐Boirazian, Frauke Naumann‐Winter et al. · Molecular Therapy · 2023 · 16 citations · Full text

Medicine, Molecular Medicine, Gene Delivery +16